0001209191-22-041053.txt : 20220706
0001209191-22-041053.hdr.sgml : 20220706
20220706160456
ACCESSION NUMBER: 0001209191-22-041053
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220705
FILED AS OF DATE: 20220706
DATE AS OF CHANGE: 20220706
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Plavsic Mark
CENTRAL INDEX KEY: 0001868719
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36076
FILM NUMBER: 221068662
MAIL ADDRESS:
STREET 1: C/O FATE THERAPEUTICS, INC.
STREET 2: 3535 GENERAL ATOMICS COURT STE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: FATE THERAPEUTICS INC
CENTRAL INDEX KEY: 0001434316
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 651311552
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12278 SCRIPPS SUMMIT DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92131
BUSINESS PHONE: 858.875.1803
MAIL ADDRESS:
STREET 1: 12278 SCRIPPS SUMMIT DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92131
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-07-05
0
0001434316
FATE THERAPEUTICS INC
FATE
0001868719
Plavsic Mark
C/O FATE THERAPEUTICS, INC.
12278 SCRIPPS SUMMIT DRIVE
SAN DIEGO
CA
92131
0
1
0
0
Chief Technical Officer
Common Stock
2022-07-05
4
S
0
3719
24.61
D
127123
D
Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 9,500 shares of Common Stock underlying restricted stock units granted to the Reporting Person on June 14, 2021. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
Represents the weighted average sale price of the shares sold from $24.34 to $24.82 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2.
/s/ Cindy Tahl, as Attorney-in-Fact
2022-07-06